CANG
Cango Inc.
There isn't enough reported data to score CANG yet.
LCID
Lucid Group, Inc.
LCID lost money over the past year, so it has no meaningful PE right now. Analysts expect losses to shrink, though they disagree widely on how much.
CANG Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Healthy | |
| Unavailable | |
| Strong |
CANG's profitability and balance sheet are currently healthy. There isn't enough data to rate its revenue and cash flow.
LCID Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Weak | |
| Unavailable |
LCID's revenue is currently healthy, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
CANG PE Valuation
CANG has no meaningful PE right now: it lost money over the past year.
LCID PE Valuation
LCID has no meaningful PE right now: it lost money over the past year.
CANG Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong decline | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect CANG's losses to shrink, with revenue declining.
LCID Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect LCID's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
CANG Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q4 2024 | $0.97 | +$1.09 |
| Q4 2023 | -$0.12 | +$2.93 |
| Q4 2022 | -$3.05 | -$3.02 |
| Q3 2022 | -$1.17 | -133% |
| Q2 2022 | -$1.89 | -121% |
| Q1 2022 | $0.30 | -96% |
| Q4 2021 | -$0.03 | -100% |
| Q3 2021 | $3.54 | -26% |
CANG has the stronger earnings trend. Trailing diluted EPS is down 49% for CANG versus LCID down 224%.
LCID Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$13.08 | -$2.57 |
| Q2 2026 | -$13.65 | -$2.35 |
| Q1 2026 | -$13.15 | -$1.25 |
| Q4 2025 | -$12.09 | +$0.41 |
| Q3 2025 | -$10.51 | +$2.49 |
| Q2 2025 | -$11.30 | +$0.40 |
| Q1 2025 | -$11.90 | +$0.40 |
| Q4 2024 | -$12.50 | +$1.10 |
LCID is still losing money, but less than at its worst: $13.08 per share over the past year, against $16.50 at its worst in mid-2023.
CANG Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2025 | $404.1M | +235% |
| Q4 2024 | $120.7M | -53% |
| Q4 2023 | $255.4M | +249% |
| Q4 2022 | $73.1M | -54% |
| Q3 2022 | $62.5M | -48% |
| Q2 2022 | $43.4M | -69% |
| Q1 2022 | $118.2M | -30% |
| Q4 2021 | $157.7M | -4.3% |
CANG has the stronger quarterly revenue trend. Revenue is up 453% for CANG versus up 4.1% for LCID.
| Quarter | Margin | YoY |
|---|---|---|
| Q4 2025 | -58% | -14 points |
| Q2 2025 | -72% | -26 points |
| Q4 2024 | 22% | +145 points |
| Q4 2023 | -4.3% | +20 points |
| Q4 2022 | -43% | -29 points |
| Q3 2022 | -46% | -41 points |
| Q2 2022 | -122% | -124 points |
| Q1 2022 | -24% | -38 points |
CANG's operating margin was −58% last quarter, down 14 points from the same quarter a year ago, near the bottom of its range since 2016.
LCID Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $350.3M | +4.1% |
| Q2 2026 | $405.3M | +56% |
| Q1 2026 | $282.5M | +20% |
| Q4 2025 | $522.7M | +123% |
| Q3 2025 | $336.6M | +68% |
| Q2 2025 | $259.4M | +29% |
| Q1 2025 | $235M | +36% |
| Q4 2024 | $234.5M | +49% |
LCID's revenue has grown year over year for 11 quarters in a row: $350M last quarter, up 4.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -245% | +35 points |
| Q2 2026 | -267% | +43 points |
| Q1 2026 | -350% | -56 points |
| Q4 2025 | -204% | +109 points |
| Q3 2025 | -280% | +105 points |
| Q2 2025 | -310% | +83 points |
| Q1 2025 | -294% | +128 points |
| Q4 2024 | -313% | +156 points |
LCID's operating margin was −245% last quarter, up 35 points from the same quarter a year ago, near the top of its range since 2020.
CANG Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q4 2024 | -$46.6M | -130% |
| Q4 2023 | $153.7M | +$153.7M |
| Q4 2022 | $0 | $0 |
| Q3 2022 | $0 | $0 |
| Q2 2022 | $0 | $0 |
| Q1 2022 | $0 | $0 |
| Q4 2021 | $0 | $0 |
| Q3 2021 | $0 | $0 |
CANG has the stronger cash trend. Its trailing FCF is up 365% versus its history, compared with LCID at down 75%.
LCID Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1B | -$84.2M |
| Q2 2026 | -$1.5B | -$463.2M |
| Q1 2026 | -$1.4B | -$849M |
| Q4 2025 | -$1.2B | -$417.1M |
| Q3 2025 | -$955.5M | -$333M |
| Q2 2025 | -$1B | -$271.6M |
| Q1 2025 | -$589.9M | +$125.1M |
| Q4 2024 | -$824.8M | -$77.6M |
LCID has burned cash in almost every quarter: −$5.2B over the past year, against −$3.4B the year before.
CANG Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -9.5% | -4.4M shares |
| 1 year | -23% | -12.4M shares |
| 3 years | -30% | -17.9M shares |
| 5 years | -17% | -8.4M shares |
| Available history | -17% | -8.4M shares |
CANG has the edge over LCID on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2024 | $13.6M |
| Q4 2023 | $37M |
| Q4 2022 | — |
| Q3 2022 | — |
| Q2 2022 | — |
| Q1 2022 | — |
| Q4 2021 | — |
| Q3 2021 | — |
LCID Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.3% | +12.5M shares |
| 1 year | +26% | +82.4M shares |
| 3 years | +73% | +166M shares |
LCID has 395M diluted shares, up 26% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | $2.2M |
| Q1 2020 | — |
CANG Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2024 | -4.4x | Net Cash |
| Q4 2021 | 3.1x | Elevated |
| Q3 2021 | 4.0x | Elevated |
| Q2 2021 | 2.3x | Moderate |
| Q1 2021 | 1.5x | Healthy |
| Q4 2020 | 3.4x | Elevated |
| Q3 2020 | 4.0x | High |
| Q2 2020 | 0.8x | Very low |
CANG has more cash than debt.
LCID Net Leverage
LCID's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
CANG Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 39.8 | Neutral |
| Stochastic | 9.7 | Oversold |
CANG's weekly RSI is 40 (neutral) and its Stochastic is 10 (oversold).
LCID Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 32.9 | Neutral |
| Stochastic | 7.1 | Oversold |
LCID's weekly RSI is 33 (neutral) and its Stochastic is 7 (oversold).
CANG PE vs Consumer Cyclical Sector
| Metric | CANG | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 18x | — |
CANG has no meaningful PE right now: it lost money over the past year.
LCID PE vs Consumer Cyclical Sector
LCID has no meaningful PE right now: it lost money over the past year.
CANG Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.09 | 24% below |
| 20 week MA | $2.03 | 22% below |
| 50 week MA | $5.48 | 71% below |
| 100 week MA | $13.7 | 88% below |
| 200 week MA | $10.7 | 85% below |
CANG is in a downtrend: it's below all five of its weekly moving averages, and 85% below its 200-week average.
LCID Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.53 | 7.9% below |
| 20 week MA | $4.88 | 33% below |
| 50 week MA | $7.33 | 56% below |
| 100 week MA | $15.4 | 79% below |
| 200 week MA | $31.9 | 90% below |
LCID is in a downtrend: it's below all five of its weekly moving averages, and 90% below its 200-week average.
CANG Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $43.0 | $36.3 | -16% |
| 2021 | $36.3 | $16.1 | -56% |
| 2022 | $16.1 | $6.70 | -58% |
| 2023 | $6.70 | $5.10 | -24% |
| 2024 | $5.10 | $24.6 | +382% |
| 2025 | $24.6 | $13.9 | -43% |
| 2026 YTD | $13.9 | $1.59 | -89% |
CANG's yearly returns have swung widely, from +382% in 2024 to −58% in 2022. It's down 89% so far in 2026.
LCID Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $98.9 | $100.4 | +1.5% |
| 2021 | $100.4 | $376.4 | +275% |
| 2022 | $376.4 | $67.0 | -82% |
| 2023 | $67.0 | $42.1 | -37% |
| 2024 | $42.1 | $32.0 | -24% |
| 2025 | $32.0 | $11.4 | -64% |
| 2026 YTD | $11.4 | $3.25 | -72% |
LCID has the edge over CANG on returns for 2026, with the stronger performance.